Huntington National Bank lessened its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 567,945 shares of the company’s stock after selling 18,061 shares during the quarter. Johnson & Johnson comprises about 1.3% of Huntington National Bank’s investment portfolio, making the stock its 9th biggest holding. Huntington National Bank’s holdings in Johnson & Johnson were worth $79,353,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Stifel Financial Corp increased its stake in shares of Johnson & Johnson by 6,715.9% during the third quarter. Stifel Financial Corp now owns 2,572,663 shares of the company’s stock valued at $334,777,000 after acquiring an additional 2,534,918 shares during the period. Cornerstone Investment Partners LLC increased its stake in shares of Johnson & Johnson by 91.4% during the fourth quarter. Cornerstone Investment Partners LLC now owns 1,512,352 shares of the company’s stock valued at $211,306,000 after acquiring an additional 722,113 shares during the period. Schwab Charles Investment Management Inc. grew its position in Johnson & Johnson by 4.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 12,576,360 shares of the company’s stock worth $1,757,159,000 after buying an additional 551,632 shares during the last quarter. Atlantic Trust Group LLC grew its position in Johnson & Johnson by 23.4% in the third quarter. Atlantic Trust Group LLC now owns 2,060,040 shares of the company’s stock worth $267,827,000 after buying an additional 391,068 shares during the last quarter. Finally, Fisher Asset Management LLC grew its position in Johnson & Johnson by 2.8% in the fourth quarter. Fisher Asset Management LLC now owns 12,127,379 shares of the company’s stock worth $1,694,437,000 after buying an additional 329,705 shares during the last quarter. Institutional investors and hedge funds own 67.40% of the company’s stock.
Johnson & Johnson stock opened at $123.85 on Friday. Johnson & Johnson has a 52 week low of $125.00 and a 52 week high of $125.73. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.58 and a quick ratio of 1.25. The company has a market capitalization of $336.30 billion, a P/E ratio of 16.97, a PEG ratio of 1.92 and a beta of 0.74.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The firm had revenue of $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. During the same quarter last year, the business posted $1.83 EPS. The company’s revenue was up 12.6% on a year-over-year basis. equities analysts forecast that Johnson & Johnson will post 8.13 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 12th. Investors of record on Tuesday, May 29th will be paid a $0.90 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.84. The ex-dividend date of this dividend is Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.91%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.03%.
JNJ has been the topic of several recent research reports. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Monday, January 22nd. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $152.28 price target on the stock in a research report on Tuesday, January 23rd. BTIG Research restated a “sell” rating and issued a $110.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Stifel Nicolaus lifted their price target on shares of Johnson & Johnson from $142.00 to $145.00 and gave the stock a “hold” rating in a research report on Wednesday, January 24th. Finally, Citigroup decreased their price target on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $142.23.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.